In This Article:
Daxor’s Blood Volume Analysis (BVA) Technology Takes Center Stage at SCCM 2025
Oak Ridge, TN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress at the Orange County Convention Center in Orlando, FL from February 23 through February 25, 2025. The Company will be exhibiting at Booth #532.
"With 5.7 million annual ICU admissions costing $108 billion in the United States, and scores of affirming peer-reviewed studies, including a randomized controlled trial, Daxor’s blood volume analysis (BVA) has demonstrated significant impact on patient outcomes - altering fluid and red blood cell interventions in 44% of cases and reducing mortality by 66% in surgical intensive care units, while decreasing hospital stays and ventilator days. This conference offers a strategic platform to showcase how our innovative solution reshapes patient care and healthcare economics," said Michael Feldschuh, Daxor CEO and President.
About Society of Critical Care Medicine
The Society of Critical Care Medicine (SCCM) is the largest nonprofit medical organization dedicated to promoting excellence and consistency in the practice of critical care. With members in more than eighty countries, SCCM is the only organization that represents all professional components of the critical care team. The Society offers a variety of activities that ensure excellence in patient care, education, research, and advocacy.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.